期刊文献+

健康志愿者静滴甲磺酸加替沙星氯化钠注射液耐受性研究 被引量:2

The clinical tolerance of gatifloxacin mesilate after intravenous infusion in Chinese health volunteers
下载PDF
导出
摘要 目的 :在中国健康成年志愿者中评价单次静滴甲磺酸加替沙星氯化钠注射液的安全性、耐受性。方法 :根据新药临床试验指导原则设计试验方案 ,并获得伦理委员会批准。受试者须自愿签署知情同意书。选择 4 8名 1 8~ 5 0岁健康成人 ,用区组随机化设计方法 ,将受试者随机分为 1 0 0 ,2 0 0 ,30 0 ,4 0 0 ,5 0 0 ,6 0 0 ,70 0 ,80 0mg剂量组。观察临床症状体征并严密观察记录试验期间发生的不良事件。结果 :各组受试者体检及实验室检查各项指标均在正常范围 ,具较好可比性。给药后生命体征和各种实验室检查等未见有临床意义的改变。试验中未见严重不良反应。结论 :健康受试者单次静滴甲磺酸加替沙星氯化钠注射液 ,最大剂量至 80 0mg,比较安全 ,耐受性较好。推荐临床使用剂量为每次 4 0 0mg,qd。 OBJECTIVE To evaluate the safety and tolerance of gatifloxacin mesilate in Chinese healthy volunteers treated by single dose intravenous infusion. METHODS The clinical trial protocol was designed according to the Good Clinical Practice and passed by the ethics committee. It's necessary that all volunteers sign the informed consent. The 48 selected healthy volunteers of 18~50 years old were divided into 100,200,300,400,500,600,700 and 800 mg groups respectively by Latin method. Clinical symptoms were observed or examined before and after single dose intravenous infusion of gatifloxacin mesilate. RESULTS After single dose intravenous infusion from 100mg to 800 mg of gatifloxacin mesilate for the volunteers, the clinical symptoms were observed. The laboratory testing results were in the normal range, no serious ADRs were found, which were involved in the drug during the trial. CONCLUSIONS The single dose intravenous infusion to the Chinese healthy volunteers up to 800 mg of gatifloxacin mesilate is safe and tolerable.The dosing schedule of 400 mg /d of gatifloxacin mesilate,once a day, is recommended for clinical therapy.
出处 《中国医院药学杂志》 CAS CSCD 北大核心 2004年第4期216-218,共3页 Chinese Journal of Hospital Pharmacy
关键词 甲磺酸加替沙星氯化钠注射液 单次静滴 耐受性 gatifloxacin mesilate single dose intravenous infusion tolerance
  • 相关文献

参考文献16

  • 1Hosaka M, Kinoshita S, Toyama A, et al. Antibacterial properties of AM-1155, a new 8-methoxy quinolone[J]. J Antimicrob Chemther, 1995,36 : 293.
  • 2Tomioka H, Saito H, Sato K. Comparative antimycobacterial activities of the newly synthesized quinolone AM-1155, sparfloxacin and ofloxacin[J ]. Antimicrob Agents Chemother, 1993,37 (6):1259.
  • 3Wakabayshi E, Mitsuhashi S. In vitro antibacterial activitiy of AM-1155, a novel6-fluoro-8-melhoxy quinolone[J ]. Antimicrob Agents Chemother, 1994,38 (3) :594.
  • 4Appelbaum PC. Quinolonc activity against anaerobes[J]. Drugs,1999,58 (2):60.
  • 5Miyashita N, Niki Y, Kishimono T,et al. In vitro and in vivo activities of AM-1155, a new fluorcyquinolone gainst Chlamydia spp[J].Antimicrob Agents Chemother, 1997,41 (6):1331.
  • 6Takei M, Fukuda H, Yasue T, et al. Inhibitory activities of gatifloxacin (AM-1155), a newly developed fluoroquinolone, against bacterial and mammalian type 11 toposiomerase [J ]. Antimicro Agents Chemother, 1998,42 (20) ;2678.
  • 7Lober S, Ziege S, Rau M, et al. Phamacokinetics of gatifoxacin and interaction with an antacid containing aluminum and magnesium[J]. Antimicrob Agents Chemother, 1999, 43 (5) : 1067.
  • 8Stahlberg HJ, Gohler K, Guillane M, et al. Effects of gatifloxacin (GTX) on the pharmacokinedcs of theophyline in heathly young volunteers [ abstract][ J ]. J Amimicrob Chemther,1999, 44 (1):136.
  • 9Hosaka M, Kinoshita S, Toyama A, et al. Antibacterial properties of AM-1155, a new 8-methoxy quinolone[J]. J Antimicrob Chemther,1995,36:293.
  • 10Tomioka H, Saito H, Sato K. Comparative antimycobacterial activities of the newly synthesized quinolone AM-1155, sparfloxacin and ofloxacin[J]. Antimicrob Agents Chemother, 1993,37 (6):1259.

同被引文献10

  • 1吕建平,赖清英.加替沙星与左氧氟沙星治疗泌尿生殖系统感染的成本-效果分析[J].中国医院用药评价与分析,2005,5(1):44-46. 被引量:14
  • 2Biedenbach DJ,Sutton LD,JonesRN.Antimierobial activity of CS2940,a new trifluorinated quinolone[J].Antimicrob Agents Chemother,1995,39(10):2325-2330.
  • 3Masuda N,Hideyuki F,Takahashi Y,et al.In vitro and in vivo antibacterial activities of CS-2940,a new 6-fluoro-8-(2)difluoromethoxy quinolone[J].J Antimierob Agents Chemother,1996,40(5):1201-1207.
  • 4Owens RC,Ambrose PG.Torsdes de pointes associated with fluoroquinolones[J].Pharmacotherapy,2002,22(5):663-672.
  • 5Noel GJ,Natarajan J,Chien S,et al.Effects of three fluroquinolones on QT interval in healthy adults after sigle deses[J].Clin Pharmacolther,2003,73(4):292-295.
  • 6Yan GX,Rials SJ,Wu Y,et al.Ventricular hypertrophy amplifies transmural repolarization dipersion and induces early after depolarization[J].Am J Physiol Heart Circ Physiol,2001,281(5):H1968-H1975.
  • 7B Darpo,T Nebout,PT Sager.Clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential of non-antiarrhythmic drugs[J].J Clin Pharmacol,2006,46:498-507.
  • 8Theresa CP,Mare RP,Philip AW,et al.Role of CYP1A2 and CYP2E1 in the pentoxifylline eiprefloxacin drug interaction[J].Biochem Phannacol,2004,68(2):395-402.
  • 9Liu L,Pang X,Zhang D,et al.Determination of caderofloxacin lactate in rat plasma by high-performance liquid chromatographymass spectrometry and its application in rat pharmacokinetic studies[J].J Pharm Biomed Anal,2007,45(5):799-803.
  • 10Takei M,Fukuda H,Yasue T,et al.Inhibitcry activities of gatibacterial (AM-1155),a newly developed fluoroquinolone,against bacterial and mammalian type topoisomerase[J].Antimicro Agents Chemother,1998,42 (20):2 678

引证文献2

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部